383 related articles for article (PubMed ID: 37449845)
1. Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
Valdivia A; Vagadia PP; Guo G; O'Brien E; Matei D; Schiltz GE
J Med Chem; 2023 Jul; 66(14):9445-9465. PubMed ID: 37449845
[TBL] [Abstract][Full Text] [Related]
2. Transglutaminase 2 has higher affinity for relaxed than for stretched fibronectin fibers.
Selcuk K; Leitner A; Braun L; Le Blanc F; Pacak P; Pot S; Vogel V
Matrix Biol; 2024 Jan; 125():113-132. PubMed ID: 38135164
[TBL] [Abstract][Full Text] [Related]
3. The Outside-In Journey of Tissue Transglutaminase in Cancer.
Sima LE; Matei D; Condello S
Cells; 2022 May; 11(11):. PubMed ID: 35681474
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
Yakubov B; Chen L; Belkin AM; Zhang S; Chelladurai B; Zhang ZY; Matei D
PLoS One; 2014; 9(2):e89285. PubMed ID: 24586660
[TBL] [Abstract][Full Text] [Related]
5. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
Sima LE; Yakubov B; Zhang S; Condello S; Grigorescu AA; Nwani NG; Chen L; Schiltz GE; Arvanitis C; Zhang ZY; Matei D
Mol Cancer Ther; 2019 Jun; 18(6):1057-1068. PubMed ID: 31015308
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
7. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
Soluri MF; Boccafoschi F; Cotella D; Moro L; Forestieri G; Autiero I; Cavallo L; Oliva R; Griffin M; Wang Z; Santoro C; Sblattero D
FASEB J; 2019 Feb; 33(2):2327-2342. PubMed ID: 30285580
[TBL] [Abstract][Full Text] [Related]
8. Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.
Kanchan K; Fuxreiter M; Fésüs L
Cell Mol Life Sci; 2015 Aug; 72(16):3009-35. PubMed ID: 25943306
[TBL] [Abstract][Full Text] [Related]
9. The Role of Transglutaminase 2 in Cancer: An Update.
Zaltron E; Vianello F; Ruzza A; Palazzo A; Brillo V; Celotti I; Scavezzon M; Rossin F; Leanza L; Severin F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474044
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies.
Cardoso I; Stamnaes J; Andersen JT; Melino G; Iversen R; Sollid LM
FEBS J; 2015 Jun; 282(11):2063-75. PubMed ID: 25808416
[TBL] [Abstract][Full Text] [Related]
11. Tissue transglutaminase: a multifunctional and multisite regulator in health and disease.
Yao Z; Fan Y; Lin L; Kellems RE; Xia Y
Physiol Rev; 2024 Jan; 104(1):281-325. PubMed ID: 37712623
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
13. Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.
Navals P; Rangaswamy AMM; Kasyanchyk P; Berezovski MV; Keillor JW
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672511
[TBL] [Abstract][Full Text] [Related]
14. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
[TBL] [Abstract][Full Text] [Related]
15. Nitrosylation of tissue transglutaminase enhances fibroblast migration and regulates MMP activation.
Kurt-Celep İ; Nihan Kilinc A; Griffin M; Telci D
Matrix Biol; 2022 Jan; 105():1-16. PubMed ID: 34763097
[TBL] [Abstract][Full Text] [Related]
16. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.
Wang Z; Collighan RJ; Gross SR; Danen EH; Orend G; Telci D; Griffin M
J Biol Chem; 2010 Dec; 285(51):40212-29. PubMed ID: 20929862
[TBL] [Abstract][Full Text] [Related]
17. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.
Wang Z; Collighan RJ; Pytel K; Rathbone DL; Li X; Griffin M
J Biol Chem; 2012 Apr; 287(16):13063-83. PubMed ID: 22298777
[TBL] [Abstract][Full Text] [Related]
18. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
Wang Z; Perez M; Caja S; Melino G; Johnson TS; Lindfors K; Griffin M
Cell Death Dis; 2013 Sep; 4(9):e808. PubMed ID: 24052076
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase (TG2) and mitochondrial function and dysfunction.
Lai TS; Lin CJ; Wu YT; Wu CJ
Front Biosci (Landmark Ed); 2017 Mar; 22(7):1114-1137. PubMed ID: 28199195
[TBL] [Abstract][Full Text] [Related]
20. Implications of enigmatic transglutaminase 2 (TG2) in cardiac diseases and therapeutic developments.
Al-U'datt DGF; Tranchant CC; Al-Dwairi A; Alqudah M; Al-Shboul O; Hiram R; Allen BG; Jaradat S; Alqbelat J; Abu-Zaiton AS
Biochem Pharmacol; 2022 Jul; 201():115104. PubMed ID: 35617996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
